Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Exclusion criteria

• ✕. Invasive natural killer cell leukemia;
• ✕. Hemophagocytic syndrome;
• ✕. Primary central nervous system lymphoma or secondary central nervous system involvement;
• ✕. Relapsed or refractory ENKTL, accpeted any anti-ENKTL treatment;
• ✕. Received organ transplantation in the past;
• ✕. Participating in other clinical studies or planning to start this study is less than 4 weeks from the end of the previous clinical study;
• ✕. Patients with active autoimmune diseases requiring systematic treatment in the past two years (hormone replacement therapy is not considered systematic treatment, such as type I diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, adrenocortical dysfunction or pituitary dysfunction requiring only physiological doses of glucocorticoid replacement therapy); Patients with autoimmune diseases who do not require systematic treatment within two years can be enrolled;
• ✕. Begin the study on subjects requiring systemic glucocorticoid therapy or other immunosuppressive therapy for a given condition within 14 days before treatment \[allowing subjects to use local, ocular, intra-articular, intranasal and inhaled glucocorticoid therapy (with very low systemic absorption); and allowing short-term (\< 7 days) glucocorticoid prophylaxis (e.g., contrast agent overdose) Sensitivity) or for the treatment of non-autoimmune diseases (e.g. delayed hypersensitivity caused by contact allergens);